RemeGen Co., Ltd.: all 80 studies
Page 1 of 1. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.
- Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148 as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung CancerNot yet recruitingNCT07874282Phase 2
- Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNot yet recruitingNCT07829549Phase 3
- A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid TumorsRecruitingNCT07537881Phase 1/2
- Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung DiseaseNot yet recruitingNCT07495033Phase 3
- A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal CancerRecruitingNCT07462143Phase 2/3
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Phase 3
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07315750Phase 3
- A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)RecruitingNCT07249632Phase 3
- A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid TumorsRecruitingNCT07105215Phase 1/2
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingNCT06962865Phase 2
- A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06944496Phase 3
- Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerRecruitingNCT06642545Phase 2
- A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy SubjectsRecruitingNCT06549959Phase 1
- To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerRecruitingNCT06389006Phase 2
- To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2RecruitingNCT06378242Phase 1/2
- Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate CancerRecruitingNCT06227156Phase 2
- Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast CancerRecruitingNCT06227117Phase 2
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Phase 2/3
- DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerRecruitingNCT06178159Phase 2
- A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical CancerRecruitingNCT06155396Phase 2
- Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Phase 2
- A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT06038396Phase 1/2
- A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsRecruitingNCT06016062Phase 1/2
- RC48-ADC in Combination With Gemcitabine in High Risk NMIBC SubjectsRecruitingNCT05943379Phase 2
- RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 ExpressionRecruitingNCT05940896Phase 1
- Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular EdemaRecruitingNCT05885503Phase 3
- RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLCRecruitingNCT05821933Phase 1/2
- A Study of RC88 Combined With Sintilimab for Advanced Solid TumoursRecruitingNCT05804526Phase 1/2
- A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNot yet recruitingNCT05745740Phase 1/2
- Efficacy and Safety of RC28-E Versus AfliberceptRecruitingNCT05727397Phase 3
- A Study of Telitacicept in Lupus NephritisRecruitingNCT05680480Phase 2
- To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)RecruitingNCT05514158Phase 1
- A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaRecruitingNCT05302284Phase 3
- A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder CancerRecruitingNCT05297552Phase 2
- A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsRecruitingNCT05205850Phase 1/2
- A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)RecruitingNCT05135715Phase 2
- A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological MalignanciesRecruitingNCT04965519Phase 2
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionRecruitingNCT04714190Phase 3
- A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RecruitingNCT04400695Phase 3
- A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLCActive, not recruitingNCT06883630Phase 1
- RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerCompletedNCT06173037Phase 2
- Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast CancerWithdrawnNCT06105008Phase 2
- A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric CancerActive, not recruitingNCT05980481Phase 2/3
- A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsActive, not recruitingNCT05867303Phase 1
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Phase 3
- Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Phase 3
- A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus ErythematosusCompletedNCT05687526Phase 1
- A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's SyndromeCompletedNCT05673993Phase 3
- A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant TumorCompletedNCT05628857Phase 2
- A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid TumoursCompletedNCT05508334Phase 1/2
- Telitacicept Study in Chinese Subjects With Systemic Lupus ErythematosusCompletedNCT05247203Phase 1
- A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid TumoursCompletedNCT04914117Phase 1
- A Study of Telitacicept for Injection (RC18) in Subjects With IgA NephropathyTerminatedNCT04905212Phase 2
- Evaluation of RC28-E Injection in Diabetic RetinopathyStatus unknownNCT04782128Phase 2
- Evaluation of RC28-E Injection in Diabetic Macular EdemaCompletedNCT04782115Phase 2
- RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II TrialTerminatedNCT04625153Phase 2
- A Study of RC108-ADC in Subjects With Advanced Malignant Solid TumorsCompletedNCT04617314Phase 1
- A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract CancerActive, not recruitingNCT04329429Phase 2
- A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT04311034Phase 1/2
- A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia GravisCompletedNCT04302103Phase 2
- A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) NephropathyCompletedNCT04291781Phase 2
- Evaluation of RC28-E Injection in Wet Age-related Macular DegenerationCompletedNCT04270669Phase 1/2
- A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese SubjectsCompletedNCT04235933Phase 1
- A Study of RC98 in Subjects With Advanced Malignant Solid TumorsActive, not recruitingNCT04190823Phase 1
- A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid TumorsCompletedNCT04175847Phase 1/2
- Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)CompletedNCT04082416Phase 3
- A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's SyndromeCompletedNCT04078386Phase 2
- A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial CancerCompletedNCT04073602Phase 2
- A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial CancerCompletedNCT03809013Phase 2
- Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular DegenerationCompletedNCT03777254Phase 1
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2CompletedNCT03556345Phase 2
- A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial CancerCompletedNCT03507166Phase 2
- A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesActive, not recruitingNCT03500380Phase 2/3
- A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum DisordersTerminatedNCT03330418Phase 3
- A Study of RC48-ADC in Subjects With Advanced Breast CancerCompletedNCT03052634Phase 1/2
- A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.CompletedNCT03016013Phase 3
- Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)CompletedNCT02885610Phase 2
- A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid ArthritisTerminatedNCT02882087Phase 2
- Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid TumorsCompletedNCT02881190Phase 1
- A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid TumorsCompletedNCT02881138Phase 1